Related Experiment Video
Updated: Jun 25, 2026
16:26
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Optimizing the treatment of type 2 diabetes using current and future insulin technologies
1Department of Endocrinology, Mayo Clinic Arizona, Scottsdale, AZ, USA.
Medsurg Nursing : Official Journal of the Academy of Medical-Surgical Nurses
|March 3, 2009
Summary
Maintaining good blood glucose levels is vital for patients with type 2 diabetes, especially those undergoing surgery. Advanced insulin therapies and delivery systems offer effective ways to manage blood sugar targets.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Diabetes Management
Background:
- Optimal glycemic control is essential for improving patient outcomes in type 2 diabetes, impacting both surgical and non-surgical cases.
- Effective management of blood glucose levels remains a significant challenge in clinical practice.
Purpose of the Study:
- To highlight the importance of achieving and maintaining target blood glucose levels in patients with type 2 diabetes.
- To discuss the role of recent advancements in insulin treatment and delivery devices in diabetes care.
Main Methods:
- Literature review of current insulin therapies.
- Analysis of new insulin delivery device technologies.
- Synthesis of evidence on glycemic control in surgical and non-surgical type 2 diabetes patients.
Main Results:
- Good glycemic control significantly improves outcomes in type 2 diabetes patients.
- Novel insulin treatments and advanced delivery devices provide better tools for achieving glycemic targets.
- These advancements offer enhanced flexibility and efficacy in managing blood glucose levels.
Conclusions:
- Achieving and sustaining target blood glucose levels is critical for enhancing patient outcomes in type 2 diabetes.
- New developments in insulin therapy and delivery systems are key facilitators in reaching and maintaining glycemic goals.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...